Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 450,100 shares, an increase of 20.3% from the November 15th total of 374,100 shares. Based on an average daily trading volume, of 144,200 shares, the short-interest ratio is presently 3.1 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HBIO. Barclays PLC increased its position in shares of Harvard Bioscience by 304.4% during the 3rd quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 44,150 shares in the last quarter. Geode Capital Management LLC grew its stake in Harvard Bioscience by 2.2% during the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock worth $2,455,000 after buying an additional 19,972 shares during the last quarter. State Street Corp increased its holdings in shares of Harvard Bioscience by 1.1% during the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after buying an additional 7,763 shares in the last quarter. Harvey Partners LLC raised its stake in shares of Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after acquiring an additional 157,500 shares during the last quarter. Finally, Corsair Capital Management L.P. acquired a new position in shares of Harvard Bioscience in the 3rd quarter worth approximately $63,000. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Price Performance

Harvard Bioscience stock opened at $2.16 on Monday. The business has a 50 day simple moving average of $2.33 and a 200 day simple moving average of $2.71. Harvard Bioscience has a one year low of $1.99 and a one year high of $5.56. The company has a market capitalization of $94.22 million, a PE ratio of -6.55 and a beta of 1.27. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.